MX2012005225A - Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso. - Google Patents

Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.

Info

Publication number
MX2012005225A
MX2012005225A MX2012005225A MX2012005225A MX2012005225A MX 2012005225 A MX2012005225 A MX 2012005225A MX 2012005225 A MX2012005225 A MX 2012005225A MX 2012005225 A MX2012005225 A MX 2012005225A MX 2012005225 A MX2012005225 A MX 2012005225A
Authority
MX
Mexico
Prior art keywords
compositions
methods
substituted purine
pyrazolopyrimidine compounds
compounds
Prior art date
Application number
MX2012005225A
Other languages
English (en)
Inventor
Joseph P Lyssikatos
Zhonghua Pei
Kirk D Robarge
Wendy Lee
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012005225A publication Critical patent/MX2012005225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención se relaciona con compuestos de la Fórmula I: (ver fórmula (I) donde R1, R2, R3, A1, A2, A3, A4, Y1 e Y2 y D tienen el significado descrito aquí. La presente invención también se relaciona con composiciones farmacéuticas que comprenden tales compuestos y usos terapéuticos de los mismos.
MX2012005225A 2009-11-12 2010-11-10 Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso. MX2012005225A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26062809P 2009-11-12 2009-11-12
PCT/EP2010/067159 WO2011058025A1 (en) 2009-11-12 2010-11-10 N-7 substituted purine and pyrazolopyrimidine compounds, compositions and methods of use

Publications (1)

Publication Number Publication Date
MX2012005225A true MX2012005225A (es) 2012-07-25

Family

ID=43357941

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005225A MX2012005225A (es) 2009-11-12 2010-11-10 Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.

Country Status (12)

Country Link
US (1) US8828990B2 (es)
EP (1) EP2499143B1 (es)
JP (1) JP5572715B2 (es)
KR (1) KR101447789B1 (es)
CN (1) CN102712642B (es)
BR (1) BR112012011147A2 (es)
CA (1) CA2780018C (es)
ES (1) ES2567168T3 (es)
HK (1) HK1172328A1 (es)
MX (1) MX2012005225A (es)
RU (1) RU2515541C2 (es)
WO (1) WO2011058025A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288381B2 (en) * 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
PL2670753T3 (pl) 2011-01-31 2017-05-31 Novartis Ag Nowe pochodne heterocykliczne
AP2014007601A0 (en) 2011-10-28 2014-04-30 Novartis Ag Novel purine derivatives and their use in the treatment of disease
BR112014028881A2 (pt) 2012-05-23 2017-06-27 Hoffmann La Roche populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2017004133A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
WO2020063636A1 (zh) * 2018-09-27 2020-04-02 苏州锐明新药研发有限公司 吡唑并嘧啶化合物及制备方法与制备抗癌症药物的应用
CN112707907B (zh) * 2019-10-24 2023-05-23 张飞 嘌呤衍生物及其中间体与制备抗癌症药物的应用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) * 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS60260579A (ja) * 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
JPH04224580A (ja) 1990-12-25 1992-08-13 Nippon Soda Co Ltd ピリミジン誘導体、その製造方法及び農園芸用殺菌剤
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3290666B2 (ja) 1995-06-07 2002-06-10 ファイザー・インコーポレーテッド 複素環式の縮合環ピリミジン誘導体
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
TR200003513T2 (tr) * 1998-06-02 2001-06-21 Osi Pharmaceuticals, Inc. Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
CA2422380C (en) 2000-09-15 2009-03-24 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
ATE466581T1 (de) * 2001-12-07 2010-05-15 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
ATE466580T1 (de) * 2002-03-15 2010-05-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
AU2003242252A1 (en) * 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
DE60330485D1 (de) * 2002-07-15 2010-01-21 Merck & Co Inc Zur behandlung von diabetes
WO2004014869A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
JP4887139B2 (ja) 2003-03-25 2012-02-29 武田薬品工業株式会社 ジペプチジルペプチダーゼインヒビター
WO2004087056A2 (en) * 2003-03-28 2004-10-14 Scios Inc. BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
US7968545B2 (en) * 2003-08-05 2011-06-28 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of voltage-gated ion channels
DE602004031641D1 (de) 2003-09-25 2011-04-14 Janssen Pharmaceutica Nv Die replikation von hiv hemmende purinderivate
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US20050153989A1 (en) * 2004-01-13 2005-07-14 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN100594903C (zh) 2004-09-30 2010-03-24 泰博特克药品有限公司 Hcv抑制性双环嘧啶
US7906528B2 (en) * 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
KR20070118068A (ko) 2004-11-23 2007-12-13 레디 유에스 테라퓨틱스 인코포레이티드 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2008525422A (ja) 2004-12-23 2008-07-17 ファイザー・プロダクツ・インク 抗癌剤として有用な複素芳香族誘導体
KR20070113252A (ko) 2005-02-25 2007-11-28 쿠도스 파마슈티칼스 리미티드 2,4-디아미노-피리도피리미딘 유도체 및 이의 ｍＴＯＲ억제제로서의 용도
US7357815B2 (en) 2005-04-21 2008-04-15 Micardia Corporation Dynamically adjustable implants and methods for reshaping tissue
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
US20110034454A1 (en) 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
JP5372737B2 (ja) 2006-03-13 2013-12-18 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー Ｅｇｆｒキナーゼ阻害剤およびｅｇｆｒキナーゼ阻害剤の効果に対し腫瘍細胞を感作する薬剤を用いる併用治療
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
KR20090021155A (ko) 2006-04-26 2009-02-27 에프. 호프만-라 로슈 아게 Ｐｉ3ｋ 억제제로서의 피리미딘 유도체
AU2007243457B2 (en) * 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
BRPI0710874A2 (pt) * 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
ATE493418T1 (de) 2006-07-06 2011-01-15 Array Biopharma Inc Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
WO2008021456A2 (en) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
HUE033894T2 (en) * 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
US8357662B2 (en) 2006-09-08 2013-01-22 Worcester Polytechnic Institute Surface-based ammonium ion sensor and methods of making thereof
CN101563339A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
CN101535296A (zh) 2006-09-14 2009-09-16 阿斯利康(瑞典)有限公司 作为p13k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-苯基嘧啶衍生物
WO2008032072A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
CL2007003520A1 (es) * 2006-12-07 2008-08-22 Piramed Ltd Genentech Inc Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008071650A2 (en) 2006-12-11 2008-06-19 Galapagos N.V. Novel compounds useful for the treatment of degenerative & inflammatory diseases
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
US20080233127A1 (en) * 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds
GB0707087D0 (en) 2007-04-12 2007-05-23 Piramed Ltd Pharmaceutical compounds
MX2009010886A (es) 2007-04-12 2009-12-14 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
WO2008152394A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Pharmaceutical compounds
JP5539190B2 (ja) 2007-06-12 2014-07-02 エフ．ホフマン−ラ ロシュ アーゲー チアゾロピリミジン類及びホスファチジルイノシトール−３キナーゼのインヒビターとしてのそれらの使用
WO2008152387A1 (en) 2007-06-12 2008-12-18 F.Hoffmann-La Roche Ag Quinazoline derivatives as pi3 kinase inhibitors
CN101932587A (zh) * 2007-09-24 2010-12-29 吉宁特有限公司 噻唑并嘧啶pi3k抑制剂化合物及使用方法
AU2008312631A1 (en) 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
WO2009070524A1 (en) * 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
US20090192176A1 (en) * 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
CN102105474B (zh) * 2008-05-30 2014-01-08 健泰科生物技术公司 嘌呤pi3k抑制剂化合物及使用方法
TW201018681A (en) * 2008-07-31 2010-05-16 Genentech Inc Pyrimidine compounds, compositions and methods of use
US8288381B2 (en) 2009-11-12 2012-10-16 Genentech, Inc. N-9 substituted purine compounds, compositions and methods of use
JP6025367B2 (ja) 2011-05-12 2016-11-16 キヤノン株式会社 有機ｅｌ素子

Also Published As

Publication number Publication date
CA2780018C (en) 2015-10-20
BR112012011147A2 (pt) 2021-09-08
JP2013510818A (ja) 2013-03-28
CA2780018A1 (en) 2011-05-19
RU2012122366A (ru) 2013-12-20
EP2499143B1 (en) 2016-03-16
US20110086840A1 (en) 2011-04-14
HK1172328A1 (zh) 2013-04-19
CN102712642B (zh) 2015-08-12
ES2567168T3 (es) 2016-04-20
EP2499143A1 (en) 2012-09-19
CN102712642A (zh) 2012-10-03
KR20130029756A (ko) 2013-03-25
JP5572715B2 (ja) 2014-08-13
KR101447789B1 (ko) 2014-10-06
RU2515541C2 (ru) 2014-05-10
WO2011058025A1 (en) 2011-05-19
US8828990B2 (en) 2014-09-09

Similar Documents

Publication Publication Date Title
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MY153915A (en) Organic compounds
PH12014501179B1 (en) New bicyclic dihydroisoquinoline-1-one derivatives
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
MX2010009646A (es) Agentes terapeuticos antivirales.
MY157017A (en) Sulfonamide derivatives
IN2012DN01233A (es)
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2011012337A (es) Nuevos derivados de pirimidina y su uso en el tratamiento de cancer y de otras enfermedades.
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2019003738A (es) Compuestos antivirales.
MA33768B1 (fr) Triazolopyridines
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IN2014CN04530A (es)
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
MX2012004780A (es) Inhibidores de akt.
IN2012DN03182A (es)

Legal Events

Date Code Title Description
FG Grant or registration